{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:11:32Z","timestamp":1792793492304,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":2540,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Amgen Inc., Thousand Oaks, CA, USA","id":[{"id":"https:\/\/ror.org\/03q269m48","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1093\/annonc\/mds175","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T22:27:06Z","timestamp":1343773626000},"page":"3045-3051","source":"Crossref","is-referenced-by-count":58,"title":["Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid"],"prefix":"10.1016","volume":"23","author":[{"given":"S.","family":"Vadhan-Raj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.H.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds175_bb0010","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds175_bb0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mds175_bb0020","first-page":"163","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases","volume":"6","author":"Costa","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1093\/annonc\/mds175_bb0025","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1191\/0269216305pm1079oa","article-title":"Painful bone metastases: a prospective observational cohort study","volume":"19","author":"Clare","year":"2005","journal-title":"Palliat Med"},{"key":"10.1093\/annonc\/mds175_bb0030","doi-asserted-by":"crossref","first-page":"6236s","DOI":"10.1158\/1078-0432.CCR-06-0988","article-title":"The measurement of pain from metastatic bone disease: capturing the patient's experience","volume":"12","author":"Cleeland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds175_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0885-3924(96)00042-5","article-title":"Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group","volume":"12","author":"Vainio","year":"1996","journal-title":"J Pain Symptom Manage"},{"key":"10.1093\/annonc\/mds175_bb0040","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds175_bb0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11916-011-0201-7","article-title":"Pain management in patients with cancer: focus on opioid analgesics","volume":"15","author":"Leppert","year":"2011","journal-title":"Curr Pain Headache Rep"},{"key":"10.1093\/annonc\/mds175_bb0050","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1007\/s00520-006-0086-x","article-title":"The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?","volume":"14","author":"Azevedo Sao Leao Ferreira","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mds175_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003495-200363010-00002","article-title":"Responsible prescribing of opioids for the management of chronic pain","volume":"63","author":"Nicholson","year":"2003","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mds175_bb0060","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00520-008-0487-0","article-title":"Metastatic bone pain: treatment options with an emphasis on bisphosphonates","volume":"16","author":"von Moos","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mds175_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds175_bb0070","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/bmj.329.7470.812","article-title":"Managing metastatic bone pain","volume":"329","author":"Dewar","year":"2004","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mds175_bb0075","series-title":"Zometa (Zoledronic Acid) Injection, Concentrate for Intravenous Infusion [Prescribing Information]","author":"Novartis","year":"2009"},{"key":"10.1093\/annonc\/mds175_bb0080","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds175_bb0085","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds175_bb0090","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1093\/annonc\/mds175_bb0095","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds175_bb0100","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds175_bb0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds175_bb0110","series-title":"XGEVA (Denosumab) Injection, for Subcutaneous Use [Prescribing Information]","author":"Amgen","year":"2012"},{"key":"10.1093\/annonc\/mds175_bb0115","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D","article-title":"Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases","volume":"92","author":"Hofbauer","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds175_bb0120","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"A randomised, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in men with castration-resistant prostate cancer","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds175_bb0125","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds175_bb0130","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds175_bb0135","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds175_bb0140","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S","article-title":"Research in cancer pain. What we know and what we need to know","volume":"67","author":"Cleeland","year":"1991","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds175_bb0145","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds175_bb0150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.suponc.2010.12.004","article-title":"Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form","volume":"9","author":"Mathias","year":"2011","journal-title":"J Support Oncol"},{"key":"10.1093\/annonc\/mds175_bb0155","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","article-title":"Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer","volume":"17","author":"Weinfurt","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds175_bb0160","first-page":"CD003347","article-title":"Radioisotopes for metastatic bone pain","author":"Roque","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/12\/3045\/13787260\/mds175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T15:53:33Z","timestamp":1625154813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419374848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0923753419374848"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds175","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954691.793461478","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717954691.793462777","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717954691.793460868","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717954691.793463316","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717954691.793462455","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}